-
Mashup Score: 0
There is little information regarding the perceptions of older adults with cancer about intent of therapy, desire for disclosure of diagnosis and prognosis, treatment priorities, and influencing factors.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy is the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, detailed delineation of toxicity data is limited and has not been examined by age. We sought to examine adverse event data in patients receiving R-CHOP from the Cancer and Leukemia Group B (CALGB) 50303 trial to determine if there were differences in grade 3+ toxicities by age cohort or ECOG performance status (PS), and if outcome was impacted by age cohort or toxicity occurrence.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy https://t.co/XB5i9qIzfV @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #Toxicities https://t.co/3jdTIWn88I
-
-
Mashup Score: 0Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study - 1 month(s) ago
We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study https://t.co/kWCCTMziMS @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #AdverseEvent #OlderPatients https://t.co/itjVGv0uNL
-
-
Mashup Score: 13Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3 - 1 month(s) ago
Therapeutic advances have allowed more adults aged ≥60 years with acute myeloid leukemia (AML) to receive life-prolonging treatments, with improvement in overall survival. In contrast to other cancers, the onset of AML is often sudden, high-risk treatment decisions must be made quickly, and survival is often compromised due to aging-related conditions (e.g., functional impairments). Studies have demonstrated that up to 78 % of older adults with AML and their caregivers experience significant psychological distress.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3 https://t.co/PfjFULzPOz @MelissaLoh21 @HKlepinMD @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #SIOG #YoungSIOG #Elsevier #GeriatricAssessment https://t.co/FAm4vWe6oP
-
-
Mashup Score: 19Three lessons from “The Fox and the Grapes” to inform precision oncology in the older adult - 2 month(s) ago
Practical Applications:
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Three lessons from “The Fox and the Grapes” to inform precision oncology in the older adult https://t.co/hrwXev1pFk @chefaleixomd @ramsedhom @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier
-
-
Mashup Score: 19From healthy aging to complex needs in older adults: Onco-geriatric insights from the EuGMS 2024 conference, a report from Young SIOG - 2 month(s) ago
Comprehensive geriatric assessment (CGA) has become a crucial tool in the management of older adults with cancer. Several randomized controlled trials have demonstrated improved outcomes with integration of CGA, including improved treatment completion rates [1], decreased treatment-related toxicities [1–3], improved quality of life [1,4] (QoL), and improved treatment tolerability [1–3]. Thus, several guidelines and positions papers have recently emphasized the need for routine CGA to improve outcomes and guide treatment decisions for older patients with cancer [5–8].
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
From healthy aging to complex needs in older adults: Onco-geriatric insights from the EuGMS 2024 conference, a report from Young SIOG https://t.co/udivxu0qZ5 @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #Resilience #Frailty
-
-
Mashup Score: 18Systematic review of nutrition interventions in older patients with cancer: A synthesis of evidence and a future research priority - 2 month(s) ago
Older patients with cancer (65 years and older) are a growing population with unique nutrition-and treatment-related issues that accelerate aging. Nutrition interventions attenuate nutritional decline, muscle loss, and risk of malnutrition and sarcopenia in patients with cancer, however the evidence for older patients with cancer is limited. The aim of this systematic review was to evaluate the efficacy of nutrition interventions on nutritional status, body weight/composition and clinical outcomes in older patients with cancer and to identify future research priority areas.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Systematic review of nutrition interventions in older patients with cancer: A synthesis of evidence and a future research priority https://t.co/f031G61R6y @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #Nutritio #Malnutrition #Sarcopenia https://t.co/8ChFZxFDb0
-
-
Mashup Score: 9
Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma, predominantly afflicting older adults. There remains a notable absence of data regarding DLBCL in older adults in Latin America.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) https://t.co/VNxbgaq3cI @WilliamDale_MD @myCARG #GeriOnc https://t.co/i5Z9xKHwVK
-
-
Mashup Score: 5Association of p16(INK4a), a biomarker of cellular senescence, with receipt of therapy and frailty status among adults with plasma cell disorders - 3 month(s) ago
Multiple myeloma (MM) accounts for 19 % of hematologic malignancies diagnosed in the United States and has a higher incidence in older adults [1]. Treatment decision-making for older adults with MM is complicated by a greater prevalence of comorbid conditions and functional impairment associated with advancing age [2,3]. Biomarkers of aging have drawn attention as a means to better understand aging and its effects on older adults with cancer. The gene p16INK4a (p16) codes for a protein that blocks cyclin-dependent kinase, and greater expression is associated with cellular senescence [4].
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Association of p16(INK4a), a biomarker of cellular senescence, with receipt of therapy and frailty status among adults with plasma cell disorders https://t.co/LGrBohMp9h @ChrisJensenMD @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG https://t.co/H3f5cNZpBR
-
-
Mashup Score: 6Designing observational studies to estimate treatment effects in geriatric oncology: A closer look at confounding and its mitigation - 3 month(s) ago
Adults aged 70 or over account for more than a third of all new cancer diagnoses globally [1]. Despite continuous efforts in the last decades, the inclusion rate of older adults with cancer in clinical trials is still low [2]. In addition, many cancer treatment trials tend to enroll young, healthy patients due to use of strict eligibility criteria [3]. However, in clinical practice, patients are often older, sicker, and have poorer performance status [4], thus limiting the generalizability of clinical trial results to patients seen in clinics.
Source: www.geriatriconcology.netCategories: General Medicine News, Oncologists1Tweet-
Designing observational studies to estimate treatment effects in geriatric oncology: A closer look at confounding and its mitigation https://t.co/U1cBRxsL7k @SPilleron @LundJenny @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier https://t.co/7CtIOLjwWt
-
Treatment goals, desire for disclosure, and perception of cancer treatment outcomes in older patients with cancer: An observational study from a tertiary care center in India https://t.co/DFAdX8I7xg @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG https://t.co/q80HSh9lox